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Abstract 
The United States is facing a growing epidemic of unchecked and untreated individuals with 
prediabetes. While lifestyle interventions have remained the gold standard of treatment, has this 
been enough? A literature review was carried out to identify metformin’s role in treatment and 
management of prediabetes as well as perceived barriers to its prescribing. A total of 24 articles 
met inclusion criteria. Main findings include (a) metformin is effective in reducing the incidence 
of diabetes, though not as effective as lifestyle interventions; (b) certain populations did benefit 
more from metformin usage then other populations; (c) there was more treatment compliance 
with metformin; (d) metformin was shown to be effective in reducing microvascular 
complications often associated with diabetes; (e) while metformin was effective in reducing 
diabetes incidence, it has no effect on returning prediabetes to normal glucose ranges; (f) 
metformin was shown to be safe and tolerable; and (g) even when metformin was shown to be 
effective, it was still under prescribed and underutilized due to a knowledge gap and perceived 
barriers by primary care providers. These findings have important practice and policy 
implications, including increasing patient and provider awareness of prediabetes and its 
complications, developing guidelines regarding screening, diagnosing, and 
treatment/management of prediabetes, closing the knowledge gap and perceived barriers of 
primary care providers, and developing prevention programs that can be widely implemented. 
Further research is needed regarding the long-term implications that metformin has regarding 
prediabetes treatment and long-term patient outcomes.  
 Keywords: prediabetes, pre-diabetes, lifestyle modification, medications, 
pharmacological intervention, metformin, management, treatment, gestational diabetes, weight 
loss, pioglitazone, insulin  
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Metformin’s Role in the Prevention of T2DM in Individual’s Diagnosed with Prediabetes: 
A Systematic Literature Review 
According to the Centers for Disease Control and Prevention (2020), 88 million 
American adults have prediabetes, which equivalates to 1 out of 3 adults. Over 80percent of 
those 88 million American adults do not know they have it (Centers for Disease Control and 
Prevention [CDC], 2020). Prediabetes increases an individual’s risk of developing Type 2 
Diabetes Mellitus (T2DM), heart disease, and stroke (CDC, 2020). The following factors place 
an individual at an increased risk for prediabetes: overweight, 45 years of age or older, parent or 
sibling with T2DM, physically inactive, history of gestational diabetes, and/or polycystic ovary 
syndrome (CDC, 2020). Lifestyle changes such as increasing physical activity and dietary 
modifications are the first route to preventing prediabetes from escalating into T2DM. What 
about the individuals who continue to have high glucose levels? In cases where an individual has 
prediabetes and are considered to be at a high risk for T2DM, recent guidelines recommend 
considering use of metformin, especially for patients who are under 60 years old, have a body 
mass index (BMI) over 35 kg/m2, or have a history of gestational diabetes (JAMA, 2017). The 
question remains what role metformin plays in not only treating prediabetes, but in preventing 
T2DM or at least slowing the progression. As the 7th leading cause of death in the United States, 
diabetes is a major condition seen in clinical practice. Therefore, finding a safe and effective way 
to prevent or slow the progression of prediabetes, would be a major game-changer for our 
patient's health (ADA, n.d.)! This systematic literature review aims to examine the research 
evidence pertaining to the use of metformin in prediabetes for the prevention of T2DM. 
Recommendations for clinical practice and future research will be synthesized.  
Prediabetes Background 
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 Prediabetes occurs when serum blood glucose levels are higher than normal, though not 
high enough to be diagnosed as diabetes (American Diabetes Association [ADA], n.d.). 
Prediabetes can be diagnosed with the same tests for T2DM, with different diagnostic criteria. To 
diagnosis prediabetes, an individual has to have one of the following:  (a) glycosylated 
hemoglobin (A1C) level between 5.7 percent - 6.4 percent; (b) fasting plasma glucose  (FPG) 
level between 100 mg/dl – 125 mg/dl; or (c) oral glucose tolerance test (OGTT) level between 
140 mg/dl – 199 mg/dl (ADA, n.d.).  
 According to the National Institute of Diabetes and Digestive and Kidney Diseases 
(2017), there is an estimated 30.3 million adults in the United States alone who have diabetes 
(9.4 percent of the U.S population). Of those 30.3 million adults, 23.1 million have been 
diagnosed, while 7.2 million are undiagnosed. The statistics regarding prediabetes are even more 
staggering. An estimated 84.1 million adults in the United States have prediabetes. A total of 
23.1 million adults ages 65 or older have prediabetes and more men than women have 
prediabetes (National Institute of Diabetes and Digestive and Kidney Diseases, 2017). The 
combined total of individuals with T2DM and prediabetes, equals 114.4 million adults in the 
United States alone, equating to 43.3 percent of the adult population (National Institute of 
Diabetes and Kidney Diseases, 2017). In 2017, $327 billion, including $237 billion in direct 
medical costs and $90 billion in reduced productivity, was spent due to diagnosed diabetes 
(National Institute of Diabetes and Digestive and Kidney Diseases, 2017).   
 Prediabetes increases an individual’s risk of developing T2DM, heart disease, and stroke 
(CDC, 2019). The increased risk for cardiovascular disease in prediabetes is multifactorial, with 
etiologies including insulin resistance, hyperglycemia, dyslipidemia, hypertension, systemic 
inflammation, and oxidative stress (Hsueh, Orloski, & Wyne, 2010). When prediabetes leads to 
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diabetes, it affects the entire body, with individuals often developing major complications such 
as nephropathy, retinopathy, and peripheral neuropathy. Researchers suggest that diabetes 
doubles the risk of depression, and that risk increases as more diabetes-related health problems 
develop (CDC, 2018).  
 Known risk factors place an individual at an increased risk for prediabetes and T2DM. 
Known risk factors include, being overweight, age 45 years or older, first degree relative with 
T2DM, member of a high risk population (African American, Hispanic/Latino, American Indian, 
Alaska Native, Asian American, Pacific Islander), physical inactivity, history of gestational 
diabetes, or giving birth to an infant over 10 pounds, hypertension, low high density lipoprotein 
(HDL) cholesterol level, high triglycerides (TG) level, atherosclerotic cardiovascular disease, 
conditions associated with insulin resistance (acanthosis nigricans, non-alcoholic steatohepatitis,  
polycystic ovarian syndrome), and treatment with atypical antipsychotics or glucocorticoids 
(CDC, 2018; National Institute of Diabetes and Digestive and Kidney Diseases, n.d.). 
Prediabetes Management and Current Use of Metformin   
 Currently, screening for prediabetes is vague, often mimicking screenings for T2DM. The 
American Academy of Clinical Endocrinologists (AACE) recommends that individuals who 
meet any of the clinical risk criteria, noted above, should be screened for prediabetes or T2DM 
(AACE, n.d.). If results are normal, repeat testing at least every three years, but if an individual 
has two or more risk factors, annual screening should be considered (AACE, n.d.). Primary 
treatment goal for prediabetes is to normalize glucose and prevent the progression to diabetes 
and microvascular complications (AACE, n.d.). Therapeutic lifestyle management through a 
healthy diet, physical activity, and weight loss is the first choice in management for prediabetes. 
Therapeutic lifestyle management entails patient self-monitoring, realistic and stepwise goal 
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setting, stimulus control, cognitive strategies, social support, and appropriate reinforcement 
(AACE, n.d.). Medical nutrition therapy consists of consistency in day-to-day carbohydrate 
intake, limitation of sucrose-containing or high-glycemic index foods, adequate protein intake, 
and weight management (AACE, n.d.). Physical activity and weight loss entails individuals 
being evaluated initially for contraindications and/or limitation to increased physical activity, an 
exercise prescription should be developed for each patient based on his or her goals and 
limitations, and any new physical activity should be started slowly and built up gradually 
(AACE, n.d). In addition to therapeutic lifestyle management there are pharmacological 
approaches to glucose management in prediabetes when diet, weight loss, and physical activity 
have not been enough. Pharmacological approaches include, acarbose, thiazolidinediones, insulin 
glargine, glucagon-like peptide-1 (GLP-1) receptor agonists and metformin. Metformin is 
usually the first line option when adding a pharmacological agent as it has been shown to have 
beneficial effects on metabolic syndrome components, including mild to moderate weight loss, 
lipid profile improvements, and improved fibrinolysis (AACE, n.d.). However, due to 
inconsistent and vague guidelines regarding screenings and treatment, metformin has been 
considered underutilized and under prescribed. This systematic review delves into the research 
regarding metformin’s effectiveness compared to lifestyle modifications, safety, tolerability, 
reduction in microvascular complications and understand the barriers to prescribing.  
Clinical Question 
Based on the above phenomena of interest, the following clinical question was developed 
in PICO format to guide a systematic review of the literature: For adults with Prediabetes (P), 
does the use of metformin (I) reduce the future risk of developing T2DM Mellitus and vascular 
complications (O) when compared to the usual practice of lifestyle modification alone (C)? 
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Importance for Primary Care Providers  
 Nurse practitioners frequently work as primary care providers and will see patients 
frequently who have one or more risk factors for prediabetes and T2DM. A lack of adequate 
knowledge regarding how to screen, manage and treat prediabetes can contribute to longstanding 
future complications for the patient and family as well as unnecessary spending and cost for our 
health care system. When prediabetes is left untreated and unchecked, it has the ability to 
progress to T2DM, which can lead to microvascular complications such as hypertension, 
hyperlipidemia, heart disease, stroke, kidney disease, nerve damage, vision problems (possibly 
loss of vision), and amputations (Mayo Clinic, 2020). Lifestyle management (diet, physical 
activity and weight loss) is at the core of treatment for prediabetes and T2DM, but what about 
individuals where lifestyle management isn’t enough or barriers such as age and other medical 
conditions prevent lifestyle management? The AACE guidelines suggest metformin therapy for 
prevention of T2DM should be considered in those with prediabetes, especially for those with 
BMI over 35 kg/m2, those ages under 60 years, and women with prior gestational diabetes 
(AACE, n.d.). Unfortunately, providers are underutilizing metformin as a treatment option for 
prediabetes whether that is from a lack of knowledge, inconsistent and vague guidelines, or 
doubt regarding metformin effectiveness, efficacy and/or safety is unclear. Nurse Practitioners 
and other primary care providers need to bridge the knowledge gap regarding metformin’s use in 
treatment and management of prediabetes to provide clear cut guidelines regarding screening, 
treatment and management of prediabetes so we can all work to improve the overall health and 
well-being of diabetes patients with competence and confidence.  
Methods 
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 A systematic literature review was performed to explore the current literature as it 
pertains to the clinical question listed in the previous section. Six databases were chosen to 
provide a wide range of sources and information including CINAHL Plus with Full Test 
(CINAHL), Academic Search Premier, MEDLINE (PubMed), SAGE Journals, Google Scholar 
(GS), and Nursing and Allied Health Database. Table 1 provides rationales for choosing the six 
databases, as well as a list of search restrictions and date ranges for each database. The keywords 
prediabetes, pre-diabetes, lifestyle modification, medications, pharmacological intervention, 
metformin, prediabetes management, pre-diabetes management, prediabetes treatment, pre-
diabetes treatment, gestational diabetes, weight loss, pioglitazone, and insulin were searched 
individually and/or in combination with other keywords in all six databases (see Table 2 in 
Appendix for specific keyword combination searches). Of note, the terms gestational diabetes, 
weight loss, pioglitazone, and insulin were excluded terms, meaning they were used to specify 
that the articles were not to include these terms to help narrow down article selection.  
 The number of articles obtained in every keyword search or combination in each database 
were recorded, and searches with 15 or fewer articles were chosen for a review (see Table 2 in 
Appendix, articles for further review are bolded and marked with an asterisk). Of the articles that 
were chosen for a brief review, if they eluded a relevance to the identified clinical question or 
provided important and relevant information to the overall phenomenon these were marked for a 
more in-depth review (see Table 2 in Appendix). There were 72 articles identified, after 
eliminating duplicate articles, this review yielded 54 articles to be reviewed for inclusion or 
exclusion in the literature review. After extensively reviewing all 54 articles for relevance of the 
identified clinical question, 25 articles met the inclusion criteria.  
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 The 25 articles that met inclusion criteria directly addressed (a) the pharmacodynamics of 
metformin; (b) whether metformin alone is superior to lifestyle modifications in preventing or 
delaying the progression from prediabetes to T2DM; (c) whether metformin combined with 
lifestyle modifications is superior to lifestyle modifications alone in preventing or delaying the 
progression from prediabetes to T2DM; (d) the safety, tolerability, and cost-effectiveness of 
metformin; (e) metformin’s role in the reduction of microvascular complications that often 
coincide with T2DM; (f) barriers to screening/diagnosing prediabetes and barriers to prescribing 
metformin; and (g) specific population where metformin may reign superior to lifestyle 
modification alone. The 29 articles that met exclusion criteria directly addressed (a) lifestyle 
modification alone (no inclusion of metformin or pharmacological interventions), (b) an 
incorrect target population (i.e., pediatrics and adolescents only), (c) incorrect disease 
progression (i.e., volunteers/patients/participants already diagnosed with T2DM), and (d) 
language barrier, such as those available only in Spanish (see Table 3 in Appendix for specific 
detail regarding the rational for exclusion and inclusion of each article).  
 The 25 articles chose for the literature review were read in entirety and analyzed for 
identification of study purpose, population/size/setting, level of evidence, variables/instruments, 
findings, and implications for practice. The Hierarchy of Evidence (Melynk & Fineout-Overholt, 
2015) was used to identify the strength of the research evidence according to levels. The highest 
level of evidence obtained were two level I studies, which were systematic reviews of metal-
analyses or randomized control trials. There were nine level II studies included, which were all 
randomized control trials. Two level III articles were identified, one being a retrospective cohort 
study and the other an observational study. There were four level IV studies included, with a mix 
of cross-sectional analysis and scoping review of literature. Level V had seven articles included, 
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all of which were expert opinion (see Table 4 in Appendix for further detail on level of evidence 
and data abstraction of included articles). 
 The search methods used for this systematic literature review included a variety of 
databases and wide range of keywords, which yielded a variety of high-level evidence articles 
that applied to the clinical question. The search methods yielded a high number of articles which 
provided the ability to be detailed in the exclusion/inclusion criteria to obtain the highest quality 
and level of evidence data out there for this specific phenomenon. Other databases, such as 
Cochrane could have been included and may have provided more systematic reviews. These 
methods yielded a strong body of evidence with nearly half of the studies at a level I or II.   
Literature Review 
Pharmacodynamics of Metformin   
 Metformin is the world’s most prescribed anti-diabetic drug and is effective in 
delaying/preventing T2DM in people at high risk, by lowering body weight, fat mass, and 
circulating insulin levels through mechanisms that aren’t completely understood (Coll et al., 
2019). Metformin’s pharmacological mechanisms of action is that it decreases hepatic glucose 
production, decreases intestinal absorption of glucose, and improves insulin sensitivity by 
increasing peripheral glucose uptake and utilization (FDA, 2006). However, even though these 
mechanisms of action of metformin have been identified, they do not sufficiently explain the 
beneficial weight loss promoting effects (Coll et al., 2019). Recent studies have seen an 
association between metformin and circulating levels of GDF-15. GDF-15 is a peptide hormone 
produced by cells responding to a wide range of stressors and acts through a receptor complex 
solely expressed in the hindbrain, where it suppresses appetite and thereby food intake (Coll et 
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al., 2019). It was proposed through this association that metformin’s effect to lower body weight 
as well as other effects in prediabetes involves the elevation of circulating levels of GDF-15 
(Coll et al., 2019). In a randomized placebo-controlled trial of metformin, GDF-15 was measured 
in participants without diabetes over a period of 18 months (Coll et al., 2019). Over that period, 
participants receiving metformin lost significantly more weight compared to placebo and 
correlated with higher levels of GDF-15 (Coll et al., 2019). It was found that weight loss was 
positively correlated to the levels of plasma GDF-15 (Coll et al., 2019). In this same study, wild-
type mice were given oral metformin and were shown to have increased circulating GDF-15 with 
GDF-15 expression increasing predominately in the distal intestine and kidney (Coll et al., 
2019). When provided with a high fat diet and administered metformin, metformin prevented 
weight gain, but not in mice lacking GDF-15 or its receptor glial-cell-line-derived neurotrophic 
factor family receptor alpha like (GFRAL) (Coll et al., 2019). Essentially, metformin worked at 
preventing weight gain only in mice that had the peptide hormone GDF-15.  
Metformin was also found to have effects on energy intake, energy expenditure, insulin 
sensitization, and insulin tolerance that all required GDF-15 (Coll et al., 2019). Metformin is the 
only glucose-lowering medication or therapy that has been found to acutely increase serum 
GDF-15 levels, especially in patients with insulin resistance or T2DM (Coll et al., 2019). 
Knowing that GDF-15 signals through a specific receptor complex through the hindbrain to 
reduce body weight and that metformin has the ability to increase GDF-15 is a major 
development in the prevention or delaying of T2DM in prediabetic patients because weight loss 
is one of the primary goals of prediabetic and diabetic treatment. These findings open avenues 
into more research as to the role metformin plays in diabetes and beyond. According to Day et al. 
(2019):  
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There are currently over 1,500 registered clinical trials to test the effects of metformin in 
different diseases, including cancers, cardiovascular disease and even ageing. Mice 
overexpressing GDF15 have enhanced lifespan and are protected from atherosclerotic 
cardiovascular disease. These phenotypes are remarkably similar to those induced by 
metformin, which also reduces cardiovascular disease and potentially improves lifespan. 
Therefore, the possibility that GDF15 has a causal role in multiple beneficial effects of 
metformin treatment warrants further investigation (p. 1206).  
 These findings allow insight into why and how metformin prevents or delays T2DM in 
prediabetic individuals. This knowledge has potential to inform providers who treat diabetic 
patients on the best and most effective treatment options available.  
Metformin Versus Lifestyle Modifications  
 Currently the gold standard and most practiced approach to treatment of prediabetes and 
delaying progression to T2DM is lifestyle modifications, including weight loss, physical activity, 
and healthy diet. It is not until the individual and disease progress to T2DM that pharmacological 
interventions such as metformin are used. Research has shown that metformin is effective in 
treating and sustaining T2DM. Can metformin be just as effective as lifestyle modifications in 
the treatment of prediabetes, whether that be in combination or solely?  
 The Diabetes Prevention Program Research Group (2002) conducted one of the biggest 
studies that compared lifestyle-modifications to metformin and their ability to reduce the 
incidence of diabetes. There were 3,234 nondiabetic persons with elevated fasting and post-load 
plasma glucose concentrations (prediabetes) that were randomly placed into a placebo, 
metformin, or lifestyle-modification program (Diabetes Prevention Program Research Group, 
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2002). The control group was given nothing, metformin group was prescribed metformin 850 mg 
twice daily and the lifestyle-modification group was given a goal of attaining a 7 percent weight 
loss and participating in at least 150 minutes of physical activity per week (Diabetes Prevention 
Program Research Group, 2002). After an average 2.8 year follow-up the incidence of diabetes 
was 11.0, 7.8, and 4.8 cases per 100 persons in the placebo, metformin, and lifestyle groups 
which equated to a reduced incidence by 58 percent in the lifestyle group and 31 percent in the 
metformin group when compared to the placebo group (Diabetes Prevention Program Research 
Group, 2002). To prevent one individual from being diagnosed with diabetes in a three-year 
period, 6.9 persons would have to participate in the lifestyle intervention program while 13.9 
would have to receive metformin (Diabetes Prevention Program Research Group, 2002). It was 
shown that lifestyle modifications and metformin both reduced the incidence of diabetes, 
however, lifestyle modifications were more effective in the side by side comparison (Diabetes 
Prevention Program Research Group, 2002). An interesting finding that came out of this study 
was regarding compliance to the two interventions. Fifty-percent of the individuals in the 
lifestyle-intervention group achieved their goal weight loss by the end of the 24 week period and 
thirty-eight percent had that goal weight loss at the most recent visit which was over a year later 
(Diabetes Prevention Program Research Group, 2002). Individuals who met the physical activity 
goal of 150 minutes seven times a week was seventy-four percent at 24 weeks and fifty-eight 
percent at the most recent visit (Diabetes Prevention Program Research Group, 2002). For the 
individuals taking the placebo and metformin pills, ninety-seven and eight four percent 
respectively were compliant (Diabetes Prevention Program Research Group, 2002). It is evident 
that compliance with taking a daily medication was far superior then lifestyle modifications such 
as health eating and physical activity and can play a key role in the success of the treatment.  
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 In a similar study to The Diabetes Prevention Program, 3,041 adults with hyperglycemia 
were randomly selected into lifestyle, metformin, or placebo groups. The dependent variables in 
this study were weight loss at 6 and 12 months; FPG at 6 months; A1C at 6 months, and post-
load glucose at 12 months with the main outcome being time to diabetes diagnosis (Maruthur et 
al., 2013). In six months, 140 individuals developed diabetes in the lifestyle group, 206 in the 
metformin group, and 258 in the placebo group (Maruther et al., 2013). In all groups, at 
attainment of optimal 6-month FPG and A1C and 12-month post-load glucose predicted a greater 
than sixty percent lower risk of diabetes (Maruther et al., 2013). It was found that there was 
certain variable that could predict decreased diabetes risk depending on what group an individual 
was assigned. For the lifestyle group, variables such as weight loss and FPG were better 
predictors of decreased diabetes risk. In the metformin group, early reduction in glycemia, 
looking at the variables of FPG, A1C and post-load glucose were stronger predictors of future 
diabetes risk than weight loss was (Maruther et al., 2013). This information could guide 
providers in management decisions based on what treatment their patient is receiving. If their 
patient is participating in lifestyle intervention, then looking at variables such as weight loss and 
FPG may be more important when understanding if their treatment is effective and their risk of 
progressing to T2DM.  
 In a trail similar to the previous two, 103 participants were divided into three groups, 
standard care, intensive lifestyle modification, intensive lifestyle modification and metformin 
(Kulkarni et al., 2018). In this trial they variables looked at were weight, fasting blood sugar, 
A1C, high-sensitivity C-reactive protein (hsCRP) (risk factor for atherosclerosis), and carotid 
intima-media thickness (CIMT) after six months (Kulkarni et al., 2018). After six months, there 
was a reduction in weight and fasting blood sugar in all three groups and A1C in the intensive 
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lifestyle modification (ILSM)+Metformin group (Kulkarni et al., 2018). Over six months the 
difference in hsCRP within the three groups were -0.12 (standard care), -0.58 (ILSM), and -.11 
(ILSM+Met) (Kulkarni et al., 2018). Regarding CIMT, there was no difference between the three 
groups at six months (Kulkarni et al., 2018). Interesting enough, in the standard care group there 
was a significant reduction in the waist-hip ratio, LDL cholesterol, and triglycerides, which was 
not seen in the other two groups (Kulkarni et al., 2018). Metformin and exercise have shown to 
reduce hsCRP and other inflammatory biomarkers in prediabetes and diabetes which reduces 
CVD risk (Kulkarni et al., 2018). This trial did not look solely at metformin compared to 
lifestyle interventions, instead looked at the combination of the two. This data suggests that 
metformin has the ability to reduce relative risk and may have the extra benefit of reducing A1C 
in combination with ILSM or solely.  
In a hallmark study, the UK Prospective Diabetes Study Group (1998) confirmed this 
finding with their study that compared metformin with the conventional group (insulin or 
sulphonyl urea therapy) and found that the metformin group had a A1C of 7.4percent compared 
to 8.0percent in the conventional group (UK Prospective Diabetes Study Group, 1998). It was 
also found that metformin, compared to conventional therapy, had risk reductions of 32percent 
for any diabetes-related endpoint, 42percent for diabetes-related death, and 36percent for all-
cause mortality (UK Prospective Diabetes Study Group, 1998). Based off these findings and the 
fact that metformin decreases the risk of diabetes related endpoints, is associated with less 
weight gain (actually aides weight loss), and has fewer hypoglycemic attacks then other 
pharmacological interventions, it was suggested that metformin be the first-line therapy (UK 
Prospective Diabetes Study Group, 1998). Sheng et al., (2019) further supports that the 
progression of diabetes could be delayed to varying degrees by lifestyle and pharmacological 
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interventions except for angiotensin-converting enzyme inhibitors, statins, sulfonylureas and 
vitamin D. “In adults with pre-diabetes, firm evidence supports the notion that lifestyle 
modifications and metformin reduces the incidence of diabetes with an average of 20percent 
relative risk reduction, while statins increase the relative risk 20percent” (Sheng et al., 2019, p. 
1). Regarding lifestyle modifications, long-term strategies that involve three factors, nutrition, 
exercise, and weight loss, contribute to an abundance of positive results such as reducing BMI, 
body weight, waist and hip circumference, systolic and diastolic pressure, fasting, and 2-h 
postprandial blood glucose, total cholesterol and by increasing HDL (Sheng et al., 2019).  
There have been a number of clinical trials that demonstrated the effectiveness of 
lifestyle and/or pharmacological therapy at preventing or delaying the progression to T2DM in 
prediabetic patients, but none have looked at the other side of the spectrum and how effective 
interventions are at returning prediabetic patients to normal glucose ranges (Perrault et al., 2009). 
Perrault et al., (2009), examined the effect of basal biologic factors, weight change, and 
prevention strategies such as intensive lifestyle intervention or metformin on the incidence of 
regression from prediabetes to normal glucose range. There were two major findings in this 
study. The first finding was that insulin secretion, and other biologic processes that are retained 
with younger age are key in restoring prediabetics to normal glucose ranges (Perrault et al., 
2009). The other finding was that through weight loss and intensive lifestyle interventions 
normal glucose ranges can be restored in prediabetic patients, meaning metformin, while 
effective in preventing progression to T2DM, it is not effective in restoring normal glucose 
ranges (Perrault et al., 2009). Weight loss was shown to be the most important aspect of 
intensive lifestyle interventions as with every 1 kg loss there was an associated 16 percent 
reduction in diabetes risk (Perrault et al., 2009). However, other aspects of intensive lifestyle 
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interventions such as healthy eating and exercise also restored normal glucose ranges, though not 
as effective as weight loss. There was one nonmodifiable predictor that could play a major role 
in prediabetes management and that was age. Younger individuals had a greater associated with 
regression to normal glucose ranges then older individuals, meaning intensive lifestyle 
interventions may be more effective in the younger population and not as effective in the older 
and therefore other strategies may come in play for prediabetes treatment as an individual ages 
(Perrault et al., 2009).  
 It has been shown that lifestyle interventions reduce the relative risk of diabetes in 
individuals with prediabetes but what happens when lifestyle interventions are no longer as 
effective in improving glycaemia? There have only been a few studies that looked at 
pharmacological effectiveness in individuals who were deemed non responders to lifestyle 
interventions (Ibrahim et al., 2018). These studies found that metformin treatment was associated 
with a thirty-one percent risk reduction for diabetes compared to placebo (Ibrahim et al., 2018). 
They also found that other pharmacological interventions such as orlistat, pioglitazone, and 
liraglutide had relative risk reduction for diabetes by thirty-seven, seventy-two, and sixty-six 
percent respectively (Ibrahim et al., 2018). The major barriers with other pharmacological 
interventions other than metformin is cost and side effects. When you consider the non-
responders to lifestyle interventions; young age at diagnosis of diabetes, relatively lower BMI, 
high rates of insulin resistance and lower thresholds for the risk factors of diabetes and compare 
metformin with lifestyle interventions that effectives becomes almost identical (Ramachandra et 
al., 2006). In a study that looked at native Asian Indians who are considered to be high risk for 
progression to diabetes, the effects of lifestyle modification, metformin, and lifestyle medication 
with metformin were compared (Ramachandra et al., 2006). They found that the relative risk 
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reduction to diabetes was 28.5 percent with the lifestyle modification group, 26.4 percent with 
the metformin group, and 28.2 percent with the lifestyle modification and metformin group 
(Ramachandra et al., 2006). To prevent 1 case of diabetes, you would have to treat 6.4 persons 
with lifestyle modifications, 6.9 with metformin, and 6.5 with lifestyle modification and 
metformin (Ramachandra et al., 2006). In individuals who are considered high risk and uniquely 
present with prediabetes where BMI and weight are not major factors, metformin can play a role 
in prevention progression to T2DM.  
 Individuals with A1C of 5.7-6.4 percent, impaired glucose tolerance, and/or impaired 
fasting glycemia should all be counseled on lifestyle modifications with the goal of 7 percent 
weight loss and moderate physical activity 150 minutes per week (Standards of Medical Care in 
Diabetes, 2012). Metformin should be the only drug considered for pharmacological intervention 
as other drugs have issues with cost, side effects and lack of research (Standards of Medical Care 
in Diabetes, 2012). Even though metformin was less effective than lifestyle interventions in 
certain studies, there may be cost saving over a 10-year period and metformin has shown to be 
effective; (a) in individuals with a BMI of at least 35 kg/m2, (b) in women with a history of 
gestational diabetes where metformin and lifestyle interventions led to a 50 percent reduction in 
risk of diabetes (Standards of Medical Care in Diabetes, 2012). It is reasonable to consider 
metformin usage in these individuals (Standards of Medical Care in Diabetes, 2012). 
In summary, research shows that lifestyle modifications were most effective in 
preventing or delaying the progression of prediabetes to T2DM, however, there were certain 
scenarios where metformin can play a significant role and be equally as effective.  
Safety and Tolerability 
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 One barrier to prescribing and administration of metformin for treatment of prediabetes is 
the safety and tolerability of metformin. Common reactions of metformin are as follows: 
diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, anorexia, 
headache, metallic taste, and rash (Epocrates, n.d.). Serious reactions can include lactic acidosis, 
anemia, and hepatotoxicity (Epocrtes, n.d.).  
 In a study conducted by the Diabetes Prevention Program Research Group found that 
gastrointestinal (GI) symptoms were more common among metformin compared with placebo 
participants, averaging 28 percent and 16 percent respectively (Diabetes Prevention Program 
Coordinating Center, 2012). Metformin participants also reported “study medication-related” GI 
symptoms more frequently than the placebo group (9.5percent vs. 1.1percent) (Diabetes 
Prevention Program Coordinating Center, 2012). GI symptoms included diarrhea, flatulence, 
nausea, and vomiting (Diabetes Prevention Program Research Group, 2002). GI symptoms did 
decline throughout the study and by year 6, rates of GI symptoms were similar in the metformin 
and placebo group (Diabetes Prevention Program Coordinating Center, 2012). Symptoms did 
vary by race/ethnicity and sex (data not provided regarding which race/ethnicity or sex reported 
higher rates of symptoms), however, overtime symptom rates became similar by demographic 
group (Diabetes Prevention Program Coordinating Center, 2012). Reports of nonserious adverse 
events such for hypoglycemia and anemia were uncommon, and no differences were reported 
between groups (Diabetes Prevention Program Coordinating Center, 2012). There were seven 
metformin and eight placebo participants that reported hypoglycemia while fifty metformin and 
thirty-eight placebo participants reported anemia (Diabetes Prevention Program Coordinating 
Center, 2012). Serious adverse events were even rarer with three reports for anemia (two 
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metformin, one placebo) and zero for lactic acidosis (Diabetes Prevention Program Coordinating 
Center, 2012).  
 During the Diabetes Prevention Program study, hemoglobin (Hgb) and hematocrit (Hct) 
levels were closely followed and it was found that average Hgb and Hct levels were the same at 
baseline and over time were slightly lower in the metformin compared to the placebo group 
(Diabetes Prevention Program Coordinating Center, 2012). Again, Hgb and Hct levels varied by 
race/ethnicity and sex, but overtime became similar (Diabetes Prevention Program Coordinating 
Center, 2012). Percent of participants with low Hgb was not significantly different between 
metformin and placebo group (11.2 percent vs. 7.6 percent) but were more different regarding 
low Hct (12.6 percent vs. 8.4 percent). Hgb and Hct changes occurred during the first year with 
stabilization shortly after (Diabetes Prevention Program Coordinating Center, 2012). Overall, 
metformin participants did have slightly higher rates of GI symptoms and nonserious adverse 
events, but these improved with time and did not ultimately affect their compliance and 
adherence to the medication regimen.  
 When comparing metformin and lifestyle modification, GI symptoms was highest in the 
metformin group, but musculoskeletal (MSK) symptoms was highest in the lifestyle-intervention 
group (Diabetes Prevention Program Research Group, 2002). MSK symptoms included myalgia, 
arthritis, and arthralgia. In this study, rates of other adverse events, hospitalization, and mortality 
were comparable (Diabetes Prevention Program Research Group, 2002). It was concluded that 
metformin and lifestyle interventions were safe in addition to being effective (Diabetes 
Prevention Program Research Group, 2002). It is important to understand that with any treatment 
option for prediabetes, there are side effects and risks, however, these regress as the longer the 
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patient is on the medication and therefore weighing benefits, risks, and side effects is extremely 
important.  
 Reduction in Macrovascular Complications  
Individuals with diabetes mellitus and prediabetes are at an increased risk for 
macrovascular complications, including coronary artery disease, atherosclerosis, and 
cardiovascular disease.  
Coronary heart disease (CHD) risk is doubled in T2DM mellitus and is the top cause of 
morbidity and mortality in T2DM (Goldberg et al., 2017). A 1 percent increase in HbA1C was 
associated with a 21 percent increased risk of CHD events and a 37 percent increase in 
retinopathy or nephropathy (Newman et al., 2017). Interventions targeting dyslipidemia, 
hypertension, and hyperglycemia have reduced CHD in the general population, however, 
diabetes-related CHD risk remains, signifying there may be limitations to benefits of 
interventions targeted at CHD in diabetics (Goldberg et al., 2017). To reduce CHD preventative 
approaches, need to be addressed and initiated as early as possible, including diabetes prevention 
itself (Goldberg et al., 2017).  
 In a study conducted with the Diabetes Prevention Program Research Group, subclinical 
atherosclerosis was assessed in individuals with coronary artery calcium (CAC) (Goldberg et al., 
2017). CAC measurements are a noninvasive tool that reflects total coronary atherosclerotic 
burden, helping predict CHD (Goldberg et al., 2017). Research found that in men but NOT in 
women, CAC severity and presence were lower in the metformin compared with the control 
group (Goldberg et al., 2017). When comparing the metformin and lifestyle group, CAC severity 
and presence were similar (Goldberg et al., 2017). Race/ethnicity and age did play a role in the 
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CAC severity and presence, with lower CAC being found in younger men (Goldberg et al., 
2017). No CAC differences were identified between the two groups (Goldberg et al., 2017). 
Metformin reduced early stages of plaque development in men and CHD events compared with 
diet and sulfonylurea placebo groups, suggesting that metformin may be beneficial in preventing 
coronary atherosclerosis in prediabetic patients (Goldberg et al., 2017). In a recent treatment 
program using metformin in subjects with HIV infection and metabolic syndrome, it was found 
that metformin reduced CAC progression compared to a placebo group (Goldberg et al., 2017).  
Of note, there was a gender difference in the effect of metformin on CAC that was 
observed in this study but has not been observed in other studies.  In women, CAC severity was 
lower, making it harder to study the effect of metformin (Goldberg et al., 2017). More than half 
of the women in the study had measurable CAC levels yet metformin did not have an effect on 
CAC presence (Goldberg et al., 2017). In this study, 36 percent of women were premenopausal, 
and it is known that atherogenesis proceeds more slowly in premenopausal women, contributing 
to the lack of effect of metformin in women (Goldberg et al., 2017).  
There was no reduction in the prevalence of clinically significant CAC in men that had 
high CAC levels compared with placebo group, meaning the effects of metformin were more 
paramount with lower levels of CAC (Goldberg et al., 2017). Lower CAC scores are associated 
with a significant increase in CHD event rate, implying that metformin has a greater effect when 
the individual has smaller and recently calcifying plaques rather than well-established lesions 
which would support the evidence that metformin has a greater effect on CAC severity in 
younger men (Goldberg et al., 2017). This could mean that metformin has less clinical efficacy 
in older men, but more testing would have to be conducted before this could be determined.  
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Of importance, lower CAC in the metformin group was noted regardless of whether 
diabetes mellitus had developed (Goldberg et al., 2017). There has been question whether 
metformin was effective in reducing vascular complications before the development of T2DM 
regardless of its ability to delay diabetes development and its use in prediabetes. Based on the 
information presented above, the sooner metformin is started before or after diabetes diagnosis 
the more of a beneficial effect it has on early stages of atherosclerosis in men, though more 
research is needed regarding its effect in women (Goldberg et al., 2017).  
Even though macrovascular complications such as CAD is the leading cause of mortality 
and morbidity for patients with T2DM, there is a lack of research or evidence regarding 
metformin’s role and ability to reduce those macrovascular complications. Metformin has been 
proven to reduce weight gain, improve glycemic control, and reduce insulin requirements, which 
all may have a direct benefit on reducing CHD and macrovascular complications. 
Barriers to Metformin Prescribing 
Metformin has been shown through research that it can be an effective new therapy for 
the treatment of prediabetes and progression to T2DM, yet Metformin continues to be under 
prescribed and underutilized in this population. The reasons as to why metformin use remains 
low are not entirely clear, however, research has set its sights on the front lines, trying to 
understand the barriers providers face when prescribing metformin for treatment of prediabetes.  
In a study that estimated the rates of prevalence, diagnosis, and treatment of impaired 
FPG (IFG) and impaired glucose tolerance (IGT) found that approximately 34.6 percent of the 
United States population met the criteria for prediabetes diagnosis and that life-style 
modification and metformin reduced the incidence of T2DM by 58 percent and 38 percent 
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respectively in just 3 years (Karve & Hayward, 2010). Yet, only 3.4 percent of the 34.6 percent 
of the individuals meeting prediabetes criteria reported that their physicians diagnosed them with 
prediabetes (Karve & Hayward, 2010). None of those individuals reported receiving metformin 
(Karve & Hayward, 2010). In a study that examined metformin prescription for diabetes 
prevention and patient characteristics that may affect metformin prescription, reported better 
results, suggesting that 3.7 percent of insured, working-age adults with prediabetes, were 
prescribed metformin over a three-year period (Moin et al., 2015). It was found that the 
prevalence of metformin prescription was higher among patients with a history of gestational 
diabetes or a BMI < 35 kg/m2, but that was still only at 7.8 percent (Moin et al., 2015). Meaning 
less than 1 of 12 high-risk patients, who met criteria based off national guidelines, received 
metformin (Moin et al., 2015). This extremely low rate is concerning given the significant 
benefits metformin potentially can offer patients.  
There are theories as to the extremely low metformin prescription rate such as physicians 
do not emphasize the importance of prediabetes to their patients, physicians do not adequately 
screen for and diagnose prediabetes, physicians do not recommend lifestyle modification to 
prediabetic patients any more intensively than normoglycemia subjects, physicians are unaware 
of metformin’s benefits or they are aware of the benefits, but find them unconvincing (Karve & 
Hayward, 2010). Tseng (2017), found that six percent of providers were able to correctly identify 
all the risk factors that should trigger screening. On average, providers were able to identify 8 out 
of the 11 risk factors with the most commonly identified risk factors being family history, 
overweight, history of gestational diabetes, dyslipidemia, hypertension, and history of heart 
disease (Tseng et al., 2017). The least-commonly identified risk factors were Hispanic and Asian 
ethnicity (Tseng et al., 2017). A total of 17 percent of providers were able to identify the 
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laboratory parameters for diagnosing prediabetes based on both FPG and A1C (Tseng et al., 
2017). Family medicine and medicine-pediatric providers were able to correctly identify the 
parameters more often than internal medicine providers (Tseng et al., 2017). When patients were 
diagnosed with prediabetes, 90 percent of providers did report close follow-up with them, often 
seeing their patients with 6 months of diagnosis (Tseng et al., 2017). As far as a management 
approach, one-quarter of providers selected the correct value regarding the minimum amount of 
weight loss recommended and nearly 30 percent answered they did not know (Tseng et al, 2017). 
Less than half of the providers selected the right answer regarding the recommended minimum 
amount of physical activity and when asked to identify the best recommended initial 
management approach only 11 percent selected a referral to a behavioral weight loss program, 
while 96 percent selected educating patient on diet and physical activity (Tseng et al., 2017).  
Providers agreed that diagnosing prediabetes is important regarding their patients’ health 
and that lifestyle modification minimizes that progression, but providers disagreed that 
metformin could do the same (Tseng et al., 2017). Lack of motivation, patient’s physical 
limitations in doing activity, and lack of weight or nutrition resources were all selected as 
barriers to lifestyle modifications and providers feel as though they need more time for 
counseling, more educational resources for patients, improved nutrition resources, and access to 
weight loss programs to improve prediabetes management (Tseng et al., 2017). Providers feel as 
though patient’s avoidance of medications, pharmacological side effects, and anticipated poor 
adherence are barriers to metformin use in prediabetes, NOT medication cost or lack of FDA 
approval for metformin use in prediabetes (Tseng et al., 2017).  
These findings highlight concern about translation of decade-old evidence support the use 
of metformin in treatment of prediabetes and diabetes prevention (Moin et al., 2015). The lack of 
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translation of a safe, evidence-based therapy for a highly prevalent epidemic is a public health 
nightmare (Moin et al., 2015). While lifestyle modification can be cost-effective, metformin has 
the potential to be cost saving (Moin et al., 2015). Ideally, all patients who meet diagnostic 
criteria would be diagnosed with prediabetes and all of them would pursue lifestyle 
interventions. Research is showing that this is simply not true. Minimally, patients should be 
educated about the potential benefits of metformin and should be offered this option as 
preventative treatment (Moin et al., 2015). However, before anything can be done, providers 
need to be educated regarding risk factors, screening, diagnosis, management, and treatment of 
prediabetes. According to Tseng (2017): 
PCPs had substantial gaps in knowledge about prediabetes that need to be addressed for 
interventions, such as the CDC prediabetes screening and prevention campaign, to be 
successful. Educating providers on screening guidelines, diagnostic criteria and 
management options will be the important first step to filling these gaps. The role of 
professional societies in improving knowledge and addressing attitudes cannot be 
underestimated. Systems changes to support provider behavior are also important. 
Despite substantial evidence for the effectiveness of DPPs, they remain underutilized. 
Reasons for this are likely complex and warrant further investigation. Expanding 
insurance coverage and the availability of these high quality, comprehensive programs 
are essential. With these changes, PCPs are optimally positioned to take a lead in curbing 
the diabetes epidemic (p. 1177).  
Special Population Needs  
Primary treatment goal for prediabetes is to normalize glucose and prevent the 
progression to diabetes and microvascular complications (AACE, n.d.). Therapeutic lifestyle 
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management through medical nutrition therapy (MNT), physical activity, and weight loss is the 
first choice in management for prediabetes. However, there are special populations that may 
benefit more from the addition of metformin due to their unique barriers that do not allow 
lifestyle interventions to be as effective.  
In a study conducted by the Diabetes Prevention Program Research Group (2002), 
lifestyle intervention alone was least effective in older participants due to their physical 
limitations, which means there needs to be a consideration regarding whether a patient can 
participate effectively in lifestyle interventions to make a difference. It was suggested that older 
patients my need to have metformin added to their treatment regimen early on due to their 
physical limitations (Diabetes Prevention Program Research Group, 2002). There are populations 
that have physical, cognitive or both barriers that can significantly limit their ability to 
participate in physical activity or follow a strict regimented diet plan. With these specific and 
unique populations, metformin may be a more appropriate first line therapy then lifestyle 
interventions.  
Another finding was that metformin was less effective in persons with a lower BMI or a 
lower FPG concentration, meaning the effectiveness of metformin may increase with FPG 
concentration and how advanced the individual is in their diabetes (Diabetes Prevention Program 
Research Group, 2002). Now, this does not mean that an individual has to have a high BMI or 
high FPG concentration for metformin to be effective, it means that metformin tends to be more 
effective when the more advanced the disease is. This is an important point because metformin 
does have an added cost and therefore the patient may not get their bang for their buck if they are 
borderline prediabetic. If a patient has a relatively low BMI and low FPG concentration but still 
considered prediabetic, the more cost-effective treatment may be lifestyle modifications. In 
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contrast, if an individual has a high BMI and high FPG concentration and is considered 
prediabetic, metformin may be the more cost-effective treatment.  
There is also evidence that metformin should be strongly considered for patients who are 
younger than 60 years of age, those with a BMI over 35 kg/m2, or those with a history of 
gestational diabetes (Moin, 2015). Nathan (2007) elaborates on that point more by stating 
patients with elevated IFG and IGT and any of the following: under 60 years of age, BMI over 
35 kg/m2, family history of diabetes in first-degree relatives, elevated triglycerides, reduced 
HDL cholesterol, hypertension, A1C greater than 6.0 percent should be treated with lifestyle 
modifications and/or metformin. When prescribing to any individual it is important to keep in 
mind that while metformin has been proven to be safe to take, precautions should be taken in 
patients with renal or hepatic insufficiency.  
Ethnicities, such as Asian Indians, Asian American, African American, Alaska Native, 
American Indian, Hispanic/Latino, Native Hawaiian, or Pacific Island that have a very high 
progression rate of IGT to diabetes, meaning they are at a high risk of progressing to T2DM if 
diagnosed with prediabetes. Individuals who are from these ethnicities may benefit from early 
intervention with metformin due to being considered high risk of progressing to T2DM solely 
due to their ethnicity (Ramahandran, 2006).  
In summary, while lifestyle interventions such as weight loss, exercise, and dietary 
modifications are considered first line treatment for prediabetes, there are unique circumstances 
and populations where barriers to lifestyle interventions present themselves. In these populations, 
metformin should be considered in addition to or first line treatment for prediabetes. However, 
weight loss, exercise, and dietary modifications should always be addressed and individualized.  
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Discussion 
 According to the Centers for Disease Control and Prevention (2019), 84 million 
American adults have prediabetes. Prediabetes increases an individual’s risk of developing 
T2DM, heart disease, and stroke (CDC, 2019). Lifestyle changes such as weight loss, increasing 
physical activity and dietary modifications are the first route to preventing prediabetes from 
escalating into diabetes type 2 or at least delaying the progression. While lifestyle changes have 
been the gold standard for quite some time, there is still a T2DM epidemic occurring and 
therefore providers and society are looking for other avenues to help fight the epidemic. When 
lifestyle modifications fail to provide us with the necessary results and individuals continue to 
have high glucose levels, where do we turn? In cases where an individual has prediabetes and are 
considered to be at a high risk for T2DM, recent guidelines recommend considering use of 
metformin, especially for patients who are under 60 years old, have a BMI over 35 kg/m2, or 
have a history of gestational diabetes (JAMA, 2017). Metformin used historically for patients 
with active T2DM can play a role in preventing prediabetes from progressing to T2DM and 
developing complications.  
 As you can see, there are a lot of factors that play a role in the screening, diagnosing, and 
treatment/management of prediabetes to prevent or delay progression to T2DM. The question 
that was to be answered through this systematic review of literature was: For adults with 
Prediabetes, does the use of metformin reduce the future risk of developing T2DM Mellitus and 
vascular complications when compared to the usual practice of lifestyle modification alone? 
Through the literature review, the answer to this question is not black and white. While there is 
no denying that lifestyle interventions such as weight loss, physical activity, and healthy eating 
are effective in the treatment/management of prediabetes, metformin does play a role. Yes, 
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metformin does reduce the risk of developing T2DM compared to the usual practice of lifestyle 
modification, but is more effective in certain populations such as individuals with physical 
limitations where physical exercise is not as easy, individuals who are considered high and 
individuals who do not fit the typical “diabetes mold” (young age of onset of diabetes, a 
relatively lower BMI, with high rates of insulin resistance and lower thresholds for the risk 
factors for diabetes). In these individuals, lifestyle modification should still be considered the 
gold standard, though metformin should be considered as an additional option for treatment. 
Although diet and physical activity are effective, the sole reliance on such will not be enough, 
especially for patients who are high risk (Cefula, 2016). Pharmacological interventions, such as 
metformin, are going to need to be implemented and we cannot rely solely that diet and physical 
activity will be enough (Cefula, 2016). With the fast-paced life that many adults are living and 
the constant stress from work and raising a family, adults do not have the time, money, or 
ambition to commit to the recommended lifestyle modifications. Even though lifestyle 
modifications are considered the gold standard, they may not be realistic for all. In an ideal 
world, our diabetic patient would eat healthy and participate in moderate to strenuous activity 
150 minutes a week, but many fail to make sufficient or sustained lifestyle changes. Improved 
success may be achieved by designing a treatment plan that fits into everyday life and is 
sustainable.  
It is important to understand patients outside of the office and examine their everyday 
lives. For patients with significant time commitments and restraints that make lifestyle changes 
challenging, metformin may provide them with prevention strategies to avoiding the progression 
into T2DM. This does not mean stop educating prediabetic patients on lifestyle interventions 
such as weight loss, exercise, and dietary modifications. Rather, seek to understand that patients 
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are humans who have lives beyond the doctor’s office and in an ideal world they would eat right 
and exercise the right amount, but that is not the reality. Instead, meet your patient where they 
are at and do not set them up for failure and be a bystander as they progress into T2DM when 
you knew from the beginning that lifestyle interventions were going to be hard for them. It is 
important to educate regarding lifestyle interventions and allow your patients to try that, but it is 
also important to help them gain control of their health and metformin may provide that for 
them.  
Implications for Future Practice  
Recommendations for Clinical Practice 
 Metformin is under prescribed and underutilized. The lack of awareness of how serious 
prediabetes is and the associated risks (micro and macrovascular complications) is scary and puts 
our patients and population at high risk. There is speculation that since metformin is not 
approved by the U.S. FDA for prediabetes, providers are hesitant to prescribe it, but research is 
showing the opposite. There is a knowledge gap at the front lines that we need to combat. We 
cannot simply wait for the U.S. FDA to approve metformin for the treatment of prediabetes, we 
are in an epidemic right now and if we wait, it will be too late. Although the reasons are not 
entirely clear, providers lack of knowledge creates a barrier to broader implementation. Closing 
the knowledge gap for providers regarding screening, diagnosing, and treatment/management of 
prediabetes has to be at the forefront. Clearer guidelines regarding when to screen patients and 
who is considered at high risk need to be developed. If metformin is shown to be effective in the 
treatment of prediabetes, guidelines have to reflect this (Wang et al., 2013). Universal screening 
is needed. “Noninvasive risk scores should be used in all countries, but they should be locally 
validated in all ethnic populations focusing on cultural differences around the world” (Ibrahim et 
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al., 2018, pg. 8). Currently metformin is not approved by the U.S. FDA for prediabetes and 
therefore may be creating hesitancy to prescribe it “off label” (Moin et al., 2015). High priority 
needs to be placed on the management of prediabetes. Media campaigns to increase awareness of 
prediabetes and its consequences if left untreated could be a start to increasing public awareness.  
Other strategies to increase awareness and promote informed decision making include, 
clinical decision-making tools and physician directed and performance-based incentive programs 
(Moin et al., 2015). Cefalu et al., (2016) states that an early step in advancing preventative 
strategies for diabetes medical community is to reach an agreement on how to implement 
programs on a global level. Developing clear guidelines that help providers identify individuals 
at high risk, when to screen, diagnostic criteria, and treatment/management are necessary. These 
guidelines also need to pay special attention to pharmacological interventions and acknowledge 
their benefits in treatment of prediabetes (Cefalu et al., 2016). Understanding an individual’s 
perspectives and preferences is essential to managing prediabetes, but also understanding the 
providers’ perspectives and preferences will provide us with insight as to where the barriers lie 
and if there is a disconnect between provider and patient.  
Recommendations for Research  
 More research needs to be conducted regarding provider perceived barriers to 
pharmacological treatment, including metformin and patient perceived barriers to 
pharmacological treatment and lifestyle interventions. There needs to be an understanding of 
potential barriers to wider adoption of this safe, tolerable, evidence-based, and cost-effective 
prediabetes therapy (Moin et al., 2015). More research regarding compliance of pharmacological 
and lifestyle interventions and how compliance factors in regarding treatment success. 
Metformin is not the only pharmacological intervention and therefore future research may 
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include other medications if they prove to be effective, have a good safety profile, are tolerable, 
and are of relatively low cost (Nathan et al., 2007). Questions regarding benefits of metformin 
and lifestyle modifications need to be answered. Continuing to follow-up on study participants 
and analyzing secondary outcomes can help us gain insights into whether glucose concentrations 
can be maintained at levels below diagnostic criteria and the long-term outcomes (Diabetes 
Prevention Program Research Group, 2002). There is insufficient evidence regarding the cost-
effectiveness of treatment strategies for prediabetes and therefore, research is needed on the 
long-term cost savings for starting metformin early in prediabetic care. Research, thus far 
regarding prediabetes has included small sample sizes, relatively healthy prediabetes, and short 
follow-ups which provides us with only a fraction of information as prediabetes and T2DM can 
often be lifelong disease and therefore continued research with longer follow-up with adequate 
sample size could help reassess effects and understand long term effects of interventions 
(Kulkarni et al., 2018).  
Conclusion  
 Prediabetes has reached epidemic proportions with no signs of slowing. Prediabetes 
places individuals at an increased risk for T2DM and the associated micro and macrovascular 
complications. Currently, lifestyle interventions, such as weight loss, physical activity, and 
healthy diet are the gold standard of prediabetes and T2DM. However, pharmacological 
interventions have been gaining attention for their efficacy in the treatment of T2DM. This 
logically leads to questions regarding their role in prediabetes treatment and the prevention or 
delaying of T2DM. Research has found that lifestyle interventions and metformin are effective in 
decreasing the incidence of T2DM, although lifestyle interventions have remained most 
effective. However, most of the research has encompassed small sample sizes with relatively 
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healthy participants, in unrealistic situations. Our health care system needs to shift from being 
reactive to proactive. It is clear that we cannot continue to rely solely on lifestyle interventions to 
control this epidemic. Instead, deploying the evidence surrounding metformin use, in 
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thyrotropin levels in hypothyroid patients with pre-
diabetes. Doesn’t discuss metformin regarding pre-
diabetes control.  
Siskind, D., Friend, N., Russell, A., McGarth, J. J., Lim, C., 
Patterson, S., Flaws, D., Stedman, T., Moudgil, V., Sardinha, S., 
Suetani, S., Kisely, S., Winckel, K., & Baker, A. (2018). CoMET: A 
protocol for a randomized controlled trial of co-commencement of 
metformin as an adjustive treatment to attenuate weight gain and 
metabolic syndrome in patients with schizophrenia newly 
commenced on clozapine. BMJ Open, 8(3). 
https://doi.org/10.1136/bmjopen-2017-021000  
Excluded No focus on prediabetes and prevention of T2DM 
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Souto, S., Souto, E., Braga, D., & Medina, J. (2011). Prevention and 
current onset delay approaches of type 2 diabetes mellitus (T2DM). 
European Journal of Clinical Pharmacology, 67(7), 653–661. 
https://doi.org/10.1007/s00228-011-1038-z  
Included Reviews metformin’s role in preventing or delaying 
the onset of T2DM 
Srivastava, G., Fox, C. K., Kelly, A. S., Jastreboff, A. M., Browne, 
A. F., Browne, N. T., & Apovian, C. M. (2019). Clinical 
considerations regarding the use of obesity pharmacotherapy in 
adolescents with obesity. Obesity, 27(2), 190–204. 
https://doi.org/10.1002/oby.22385   
Excluded Focuses on the adolescent population  
Sutherland, L. L., Weiler, D. M., Bond, L., Simonson, S., & Reis, J. 
(2012). Northwest latinos' health promotion lifestyle profiles 
according to diabetes risk status. Journal of Immigrant and Minority 
Health, 14(6), 999-1005. https://doi.org/10.1007/s10903-012-9641-3 
Excluded Physical assessment for risk status of T2DM 
Tian, J., Jin, D., Bao, Q., Ding, Q., Zhang, H., Gao, Z., & Tong, X. 
(2019). Evidence and potential mechanisms of traditional Chinese 
medicine for the treatment of type 2 diabetes: A systematic review 
and meta‐analysis. Diabetes, Obesity & Metabolism, 21(8), 1801–
1816. https://10.1111/dom.13760  
Excluded Focuses on traditional Chinese medicine  
Tseng, E., Greer, R., O’Rourke, P., Yeh, H.-C., McGuire, M., Clark, 
J., & Maruthur, N. M. (2017). Survey of primary care providers’ 
knowledge of screening for, diagnosing and managing prediabetes. 
Journal of General Internal Medicine, 32(11), 1172–1178. 
https://doi.org/10.1007/s11606-017-4103-1  
Included Identifies barriers that PCPs have when screening for, 
diagnosing and managing prediabetes 
UK Prospective Diabetes Study Group. (1998). Effect of intensive 
blood-glucose control with metformin on complications in 
overweight patients with type 2 diabetes (UKPDS 34). The Lancet, 
352(9131), 854-865. https://doi.org/10.1016/S0140-6736(98)07037-
8 
Included Metformin role in treatment of newly diagnosed 
patients with T2DM 
Wang, T., Eguale, T. & Tamblyn, R. (2013). Guidelines adherence in 
the treatment of patients with newly diagnosed type 2 diabetes: A 
historical cohort comparing the use of metformin in Quebec pre and 
post-Canadian Diabetes Association guidelines. BMC Health 
Included Comparing use of metformin pre and post guideline 
change in Canada 
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Services Research, 13, 442. https://doi.org/10.1186/1472-6963-13-
442  
Weigensberg, M. J., & Goran, M. I. (2009). Type 2 diabetes in 
children and adolescents. The Lancet, 373(9677), 1743-4. 
https://doi.org/10.1016/S0140-6736(09)60961-2  
Excluded Children and adolescents, not adult. 
Li, X., Lian, F., Guo, D., Fan, L., Tang, J., Peng, J., & Tong, X. 
(2013). The rs1142345 in TPMT affects the therapeutic effect of 
traditional hypoglycemic herbs in prediabetes. Evidence-Based 
Complementary & Alternative Medicine, 1–8. 
https://doi.org/10.1155/2013/327629  
Excluded Focuses on effect of traditional herbs not metformin 
on prediabetes treatment  
Zeitler, P., Arslanian, S., Fu, J., Pinhas, H. O., Reinehr, T., Tandon, 
N., Urakami, T., Wong, J., & Maahs, D. M. (2018). ISPAD clinical 
practice consensus guidelines 2018: Type 2 diabetes mellitus in 
youth. Pediatric Diabetes, 19, 28–46. 
https://doi.org/10.1111/pedi.12719  
Excluded T2DM in youth, not adults  
Zhang, L., Zhang, Z., Zhang, Y., Hu, G., & Chen, L. (2014). 
Evaluation of Finnish diabetes risk score in screening undiagnosed 
diabetes and prediabetes among U.S. adults by gender and race: 
NHANES 1999-2010. PLoS One, 9(5). 
https://doi.org/10.1371/journal.pone.0097865  
Excluded Evaluation of Finnish Diabetes Risk Score, no 
pharmacological interventions were discussed  
 
Table 4 
Literature Review Tables of All Studies Included  











Standards of medical care 
in diabetes-2012. 
Diabetes Care, 35, S11-
63. 
Recommendations 






N/A individuals who have 
prediabetes should receive 
individualized MNT as needed 
to achieve treatment goals, 
preferably provided by a 
registered dietitian familiar 
 




with the components of 
diabetes MNT 
 
Weight loss is recommended 
for all overweight or obese 
individuals 
 
At the time of T2DM diagnosis 
initiate metformin therapy 
along with lifestyle 
interventions, unless metformin 
is contraindicated 
 
In newly diagnosed T2DM 
patients with markedly 
symptomatic and/or elevated 
blood glucose levels or A1C 
consider insulin therapy, with 
or with-out additional agents, 
from the outset 
 
If noninsulin monotherapy at 
maximal tolerated dose does 
not achieve or maintain the 
A1C target over 3–6 months 
add a second oral agent, a GLP-
1 receptor agonist, or insulin 
 
Cefalu, W., Buse, J., 
Tuomilehto, J., Fleming, 
G., Ferrannini, E., 
Gerstein, H., Bennett, P., 
Ramachandran, A., Raz, 
I., Rosenstock, J., & 
Kahn, S. (2016). Update 
and next steps for real-
world translation of 
interventions for type 2 
diabetes prevention: 
Reflections from a 
















N/A Preventive pharmacology has 
been proposed as a adjunct to 
lifestyle modification due to 
cost, reimbursement, and 
shortage of lifestyle coaches 
 
Metformin the only drug that 
has been studied long term and 
shown to be effective 
 
TZD have serious adverse 
events documented 
Early step in advancing preventive 
strategies for the diabetes medical 
community is to reach an agreement on 
how to approach programs that can be 
implemented on a global level. How do 
we design and implement diabetic 
prevention programs for prediabetes that 
are general enough to be implemented 
anywhere and in any setting 
 
Although diet and physical activity are 
effective, the sole reliance on such will 
      54 
diabetes care editors 
expert forum. Diabetes 














interventions to delay 
onset of T2DM 
 
Newer obesity and diabetes 
medications such as orlistat and 
glucagon-like peptide 1 
receptor agonists, have 
potential to be effective but are 
costly, some are injectable, and 
all require further studies. 
Making metformin at the 
moment, the best option for 
widespread use due to its 
proven effectiveness, long-term 
safety and cost-effectiveness.  
 
Metformin use has been 
minimal due to GI side effects 
and lack of perceived benefit, 
even though studies have 
shown to be beneficial 
 
After 3 years, diabetes risk was 
reduced by 28.5, 26.4, and 
28.2percent in the lifestyle, 
metformin, and combination 
groups  
 
In the follow-up DPP 
Outcomes Study, cumulative 
diabetes incidence rates still 
differed significantly 10 years 
(34 and 18percent for lifestyle 
and metformin compared with 
placebo, respectively) and 15 
years (27 and 17percent, 
respectively) after initial 
randomization into the DPP 
not be enough, especially for patients who 
are high risk. Pharmacological 
interventions are going to need to be 
implemented and we can’t rely solely that 
diet and physical activity will be enough 
 
Attention needs to be given to 
pharmacological interventions and 
acknowledge their benefits in treatment of 
prediabetes  
 
FDA approval for a new indication of 
metformin as prevention for T2DM 
would be a start  
 
 
Coll, A., Chen, M., 
Taskar, P., Rimmington, 
D., Patel, S., Tadross, J., 














Those who were allocated 
metformin lost significant 
weight and their levels of 
GDF15 were persistently 
For metformin to work properly it needs 
to increase the circulating levels of 
GDF15. The ability of metformin to aid 
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Welsh, P., Virtue, S., 
Goldspink, D., 
Miedzybrodzka, E., Tung, 
Y., Rodriguez-Cuenca, S., 
Tomaz, R., Harding, H., 
Melvin, A., Yeo, G., 
Preiss, D., … Savage, D. 
(2019). GDF15 and the 
beneficial actions of 
metformin in pre-





















elevated compared to placebo. 
9 
in weight loss is beneficial to its overall 
effectiveness.  
Day, E. A., Ford, R. J., 
Smith, B. K., 
Mohammadi-Shemirani, 
P., Morrow, M., 
Gutgesell, R., Lu, R., 
Raphenya, A., Kabiri, M., 
McArthur, A., McInnes, 
N., Hess, S., Pare, G., 
Gerstein, H., & Steinberg, 
G. (2019). Metformin-
induced increases in 
GDF15 are important for 
suppressing appetite and 
promoting weight loss. 






the secretion of a 
hepatocyte-derived 
endocrine factor that 
communicates with 
the central nervous 
system 





NA Metformin induces expression 
and secretion of growth 
differentiating factor 15 
(GDF15). 
 
An increase in serum GDF15 associated 
with weight loss in patients with T2DM 
who take metformin.  
Diabetes Prevention 
Program Coordinating 
Center. (2012). Long-term 
safety, tolerability, and 
weight loss associated 
with metformin in the 
diabetes prevention 
program outcomes study. 
Examine long-term 
safety and tolerability 
along with weight 
loss and change in 
waist circumference 















and 1,082 to the 
placebo arm  
 
Participants were 
≥ 25 years of 
Gastrointestinal symptoms 
more common in metformin 
than placebo participants but 
these symptoms declined 
overtime  
 
Hemoglobin and hematocrit 
levels slightly lower in 
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tolerance 2 h 

















at 850 mg once 
daily and 
increased by 1 
month to 850 mg 
BID unless GI 
symptoms 
warranted longer 










metformin then placebo 
participants but this was only 
observed in first year and no 
further changes occurred  
 
Body weight and waist 
circumference decreased in 
metformin then placebo 
participants (2.06 vs 0.02, 2.13 
vs 0.79) 
 
During unblinded part of trial, 
weight loss was significant in 
the metformin versus placebo 
group which was related to the 
degree of continuing metformin 
adherence  
 
Metformin reduced the 
development of diabetes by 
31percent over an average of 
2.8 years 










Program Research Group. 
(2002). Reduction in the 
incidence of type 2 
diabetes with lifestyle 
intervention or 
metformin. The New 






that place an 






prevent or delay 
development of 
diabetes 





Intervention 1 – 
standard lifestyle 
recommendation
s plus metformin 
at a dose of 850 
mg twice daily 
 
Intervention 2 – 
standard lifestyle 
recommendation
s plus placebo 
twice daily 
 






and maintain a 
weight reduction 
of at least 7 
percent of initial 
body weight 
through a healthy 
low-calorie, low-




intensity, such as 
brisk 
Average follow-up was 2.8 
years 
 
Incidence of diabetes was as 
follows; intervention 1 (7.8), 
intervention 2 (11.0), and 
intervention 3 (4.8) per 100 
persons 
 
Lifestyle intervention reduced 
incidence of diabetes by 
58percent in intervention 3 and 
31percent in intervention 1 
 
Lifestyle modification more 
effective than metformin  
 
To prevent one case of diabetes 
6.9 persons would have to 
participate in lifestyle-
intervention program and 13.9 
would have to receive 
metformin  
Lifestyle modification and metformin are 
effective at preventing or delaying 
diabetes no matter gender, race or 
ethnicity.  
 
Lifestyle modification compared to 
metformin was more effective at 
preventing or delaying diabetes, although 
both were effective 
 
Lifestyle intervention was LEAST 
effective in older participants and 
therefore need to consider whether a 
patient can participate effectively in 
lifestyle interventions to make a 
difference. Older patients may need to 
have the metformin component added due 
to their physical limitations 
 
Metformin was less effective in persons 
with a lower base-line body mass 
Index or a lower fasting plasma glucose 
concentration than in those with higher 
values for these variables – the 
effectiveness of metformin may increase 
with fasting glucose concentration and 
how advanced diabetes is  
 
Rate of gastrointestinal symptoms was 
highest in the metformin group and the 
rate of musculoskeletal symptoms was 
highest in the lifestyle-intervention group 
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walking, for at 





based off annual 
oral glucose-
tolerance test or 
semiannual 
fasting plasma 
glucose test  
 
Self-reported 
levels of leisure 
physical activity 
were assessed 






activity level was 
calculated as the 
product of the 
duration and 
frequency of 
each activity (in 
hours per week), 
weighted by an 
estimate of the 
metabolic 
equivalent of that 
activity (MET) 




– understand the whole picture where one 
intervention may be more appropriate 
(such as if a patient already has 
musculoskeletal issues or symptoms, will 
lifestyle only intervention by effective?) 
 
benefits would depend on whether 
glucose 
concentrations could be maintained at 
levels below those that are diagnostic of 
diabetes and whether the maintenance of 
these lower levels improved the long-term 
outcome – questions that need to be 
answered for future research  
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result expressed 
as the average 
MET-hours per 
week for the 
previous year 
Fujii, R., Junqueira, M., 
Restrepo, M., & Turatti, 
L. (2015). Metformin and 
intensive lifestyle 
intervention for pre-
diabetes – systematic 
review of efficacy. Value 
in Health, 18(3), 55-56.  
https://doi.org/10.1016/j.j
val.2015.03.326  
Evaluate efficacy and 
safety of metformin 
versus intensive 
lifestyle intervention 
for the treatment of 
prediabetes 













Intensive lifestyle intervention 
and metformin reduced 
incidence of T2DM but didn’t 
demonstrate that combination 
of both did so.  
 
Intensive lifestyle intervention 
and metformin reduced 
incidence of T2DM, but 
lifestyle was more effective  
Intensive lifestyle intervention and 
metformin can provide significant results. 
Treatment choice should balance benefits 
and adverse effects while integrating 
patient’s personal values and feasibility of 
each intervention.  
Goldberg, R. B., Aroda, 
V. R., Bluemke, D. A., 
Barrett-Connor, E., 
Budoff, M., Crandall, J. 
P., Dabelea, D., Horton, 
E. S., Mather, K. J., 
Orchard, T. J., Schade, 
D., Watson, K., & 
Temprosa, M. (2017). 
Effect of long-term 
metformin and lifestyle in 
the diabetes prevention 
program and its outcome 













disease risk  

























No CAC differences between 
lifestyle and placebo groups in 
either sex.  
 
CAC severity and presence 
lower among men in the 
metformin versus placebo 
groups, but no effect seen in 
women.  
Metformin may protect against coronary 
atherosclerosis in prediabetes among men 
Ibrahim, M., Tuomilehto, 
J., Aschner, P., Beseler, 
L., Cahn, A., Eckel, R. H., 
Fischl, A. H., Guthrie, G., 
Hill, J. O., Kumwenda, 
M., Leslie, R. D., Olson, 
Primary prevention 
of T2DM achievable 
through 
implementation of 







N/A Lifestyle interventions (healthy 
diet, physical activity, and 
weight control) are needed for 
prevention of diabetes. 
 
Mobile phones help facilitate 
communication between health 
professionals and general population  
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D. E., Pozzilli, P., Weber, 
S. L., & Umpierrez, G. E. 
(2018). Global status of 
diabetes prevention and 
prospects for action: A 
consensus statement. 
Diabetes/Metabolism 





weight loss, physical 
activity, and 
medications.  
Risk scores need to be assessed. 
Inclusion criteria should be 
based on combination of risk 
factors and available resources.   
Noninvasive risk scores should be used 
but validated locally for cultural 
differences in all ethnic populations  
 
Lifestyle interventions reduce 
progression, however there are studies 
that show benefits of pharmacological 
prevention as well.  
Karve, A., & Hayward, R. 
A. (2010). Prevalence, 
diagnosis, and treatment 
of impaired fasting 
glucose and impaired 
glucose tolerance in 
nondiabetic U.S. adults. 




Estimate rates of 
prevalence, 
diagnosis, and 
treatment of impaired 
fasting glucose and 
impaired glucose 
tolerance  



















34.6percent had prediabetes. 
4.8percent reported receiving a 
formal diagnosis. None 
received oral 
antihyperglycemics and 
exercise was recommended for 
31.7percent while 33.5percent 
were recommended diet 
modification. 
 
19.4percent had IFG, 
5.4percent had IGT, 9.8percent 
had both  
Knowing that interventions greatly reduce 
progression from IFG/IFT to T2DM, 
individuals are still underdiagnosed and 
undertreated.  
 
PCPs may be unaware of evidence, 
unconvinced by evidence or unclear 
regarding criteria. Education to PCPs 
needs to occur  
Kulkarni, S., Xavier, D., 
George, B., Umesh, S., 
Fathima, S., & Bantwal, 
G. (2018). Effect of 
intensive lifestyle 
modification & metformin 
on cardiovascular risk in 
prediabetes: A pilot 
randomized control trial. 





Research the effects 
of exercise and 
metformin on high-
sensitivity C-reactive 
protein (hsCRP) and 
carotid intima-media 
thickness (CIMT) 
which are markers for 
atherosclerosis and 
CVD in prediabetes 
patients, as these are 
often complications 
of T2DM 








were assigned to 
the standard arm 




(ILSM), and 35 




At six months there was a 
reduction in weight and fasting 
blood sugar in all three arms 
 
Reduction in A1C only in the 
intensive lifestyle treatment and 
metformin arm 
 
Difference in hsCRP for STD 
was -.12, ILSM was -.58, and 
ILSM + Met was -.11 over six 
months 
 
At six months there was no 
difference between the three 
Weight reduction and FBS reduction 
occurred in all three arms, meaning 
lifestyle modification and metformin play 
active roles in treatment of prediabetes  
 
There was no difference seen in hsCRP 
and CIMT in intensive lifestyle 
modification and metformin arms, which 
is contrary to other studies, but this could 
be due the inclusion of patients who were 
normoglycaemic and recently turned 
dysclycaemic within the previous year 
(meaning they were relatively new 
prediabetes)  
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arm (ILSM + 
Met) 
 









thickness of the 
posterior walls of 
bilateral 
common carotid 
arteries at two 









mg) tablets were 








arms for hsCRP, CIMT (right), 
CIMT (left)  
Trial was only conducted over a 6-month 
period which is a short duration to 
analyze changes – usually require at least 
a year 
 
 Wasn’t a significant difference in hsCRP 
levels across three arms, which is similar 
to other studies outcomes, but 
interventions with metformin and 
exercise have shown to reduce hsCRP 
and other inflammatory biomarkers in 
prediabetes which reduces CVD – again 
this could be seen if trial spanned over a 
year rather than 6 months 
 
Longer follow up with adequate sample 
size could help re-assess the effects of 




Maruthur, N. M., Ma, Y., 
Delahanty, L. M., Nelson, 
J. A., Aroda, V., White, 
N. H., Marrero, D., 
Brancati, F. L., & Clark, 
Quantify relationship 
between early 
measures of weight 
and glucose and 
subsequent diabetes 
n = 3,041 
adults  









weight loss at 6 
& 12 months, 
fasting glucose 
After 6 months, 604 
participants developed diabetes  
 
Lifestyle = 140 
Metformin = 206 
Lifestyle intervention predicts lower 
diabetes risk for weight and glucose at 6 
and 12 months  
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J. M. (2013). Early 
response to preventive 
strategies in the Diabetes 
Prevention Program. 
Journal of General 




















Level II and hemoglobin 
A1c at 6 months, 
and post-load 
glucose at 12 
months.  
 
Outcome = time 
to diabetes 
diagnosis  
Placebo = 258 
 
If patients obtained optimal 6-
month FG & A1C and 12-
month post-load glucose they 
had > 60percent lower diabetes 
risk  
When patient is taking metformin, early 
reduction in glycemia has a stronger 
correlation to diabetes risk then weight 
loss  
Moin, T., Li, J., Duru, O. 
K., Ettner, S., Turk, N., 
Keckhafer, A., Ho, S., & 
Mangione, C. M. (2015). 
Metformin prescription 
for insured adults with 
prediabetes from 2010 to 
2012: A retrospective 
cohort study. Annals of 




























analyzed all data 
independently 
and retained sole 







done using SAS 
and STATA.  
3.7percent of patients with 
prediabetes were prescribed 
metformin 
 
Women were almost two times 
more likely to be prescribed 
metformin 
 
Obese patients were almost two 
times more likely to be 
prescribed metformin 
 
Patients with 2 or more 
comorbid conditions were 1.5 
times more likely to be 
prescribed metformin  
Metformin rarely prescribed for diabetes 
prevention  
 
Need to understand potential barriers to 
safe, tolerable, evidence-based, and cost-
effective prediabetes therapy  
 
Even with evidence that metformin is 
beneficial in prediabetes treatment, it is 
still not being translated into practice  
 
Underuse of highly effective prevention 
strategy  
 
Lack of translation of a safe, evidence-
based therapy for a highly prevalent 
condition is problematic  
 
At the very minimum, patients should be 
educated regarding the potential benefits 
of metformin and ideally offered this 
option as prevention  
 
For patient with significant time 
commitments and restraints that make 
lifestyle changes challenging, metformin 
may provide them with prevention 
strategies  
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The reasons for low metformin use are 
not entirely clear, and future studies 
should examine an array of patient-, 
provider-, and organization-level factors 
that may contribute to underuse 
 
Barriers – lack of knowledge about 
evidence from providers, “off label” use – 
not approved by FDA for prediabetes, 
higher priority placed on other medical 
needs, reluctance to “medicalize” 
prediabetes, lack of awareness of 
prediabetes by patients 
 
The evidence for metformin use is 
strongest for patients younger than 60 
years, those with a BMI greater than 35 
kg/m2, or those with a history of 
gestational diabetes 
 
Potential strategies to increase awareness 
and promote informed decision making 
among this at-risk population could 
include clinical decision-making tools, 
physician directed and performance-based 
incentive programs, or media campaigns 
to increase public awareness of 
prediabetes and its consequences if left 
untreated. 
Nathan, D. M., Davidson, 
M. B., DeFronzo, R. A., 
Heine, R. J., Henry, R. R., 
Pratley, R., & Zinman, B. 
(2007). Impaired fasting 
glucose and impaired 
glucose tolerance: 
Implications for care. 
Diabetes Care, 30(3), 
753–759. 
What are IFG and 
IGT, and what is their 
natural history? 
 
What is known about 
the pathogenesis of 
IFG and IGT? 
 
How do we define 





N/A Metformin effective although 
half as effective as lifestyle 
modification, but is inexpensive 
and has virtually no long-term 
side effects 
 
Acarbose is as effective as 
metformin, but many cannot 
tolerate its GI side effects and 
is costly 
Metformin is the safest and cost-effective 
anti-diabetic medication as of today, 
however, if other medications become 
more cost-effective metformin may not be 
the best option. With that being said, 
metformin has the least amount of side 
effects and therefore may always be the 
leading anti-diabetic medication based 
solely off of side effects 
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https://doi.org/10.2337/dc
07-9920  
IFG/IGT, and can we 
alter it? 
 
Do interventions that 
prevent the 
progression from 
IFG/IGT to diabetes 
also prevent the 
development/worseni




factors, or CVD 
events? 
 
Are there adequate 
data to prevent or 
delay diabetes in 
IFT/IGT at this time? 
 
Who should be 
screening and with 




of IFG/IGT?  
 
Orlistat also has been shown to 
be effective but is poorly 
tolerated, however, now that it 
is an OTC drug, it is less costly  
 
Rosiglitazone was as effective 
in dallying/preventing diabetes 
as lifestyle modification but is 
costly and associated with a 
sevenfold increase in heart 
failure  
Patients with elevated IFG or IGT with no 
other risk factors should be treated 
through lifestyle modification (5-
10percent weight loss and moderate 
intensity physical activity – 30 min/day 
 
Patients with elevated IFG and IGT and 
any of the following: < 60 years of age, 
BMI ≥ 35 kg/m2, family history of 
diabetes in first-degree relatives, elevated 
triglycerides, reduced HDL cholesterol, 
hypertension, A1C > 6.0percent should 
be treated with lifestyle modifications 
and/or metformin 
 
Lifestyle modifications should always be 
addressed and used as a foundation; 
however, metformin has been proven 
effective to help prevent or delay the 
progression to T2DM 
 
Future recommendations 
may include other medications if they 
prove to be effective, have a good safety 
profile, are tolerable, and are of relatively 
low cost. 
Newman, J. D., 
Schwartzbard, A. Z., 
Weintraub, H. S., 
Goldberg, I. J., & Berger, 
J. S. (2017). Primary 
prevention of 
cardiovascular disease in 
diabetes mellitus. Journal 
of the American College 
of Cardiology, 70(7), 883-
893. 
Cardiovascular 
disease is major risk 
factor of T2DM and 
most common cause 
of death. Need to 
expand the use of 
therapies proven to 
reduce CVD in 





N/A Metformin generally 




strategies such as SGLT2, 
GLP-1 analogues have also 
shown to reduce vascular risk 
 
Further research is needed to 
determine if these agents are 
superior or additive in the CVD 
CVD risk reduction is critical 
 
Statins, aspirin, glucose-lowering 
therapies, and BP reduction should all be 
considered along with intensive lifestyle 
management  
 
Uniform medical therapies impact 
morbidity and mortality of diabetic 
patients  




risk reduction with the use of 
metformin  
Perreault, L., Kahn, 
Steven E., Christophi, C., 
Knowler, W., & 
Hamman, R. (2009). 
Regression from pre-
diabetes to normal 
glucose regulation in the 
diabetes prevention 





prediabetes to normal 
glucose regulation 
was associated with 
reduced incidence of 
diabetes, examined 
whether regression 
also reduced risk for 





N/A For models adjusted for age, 
sex, race, ethnicity, baseline 
A1C, and treatment odds, a 
regression to normal glucose 
regulation also lead to a lower 
prevalence of microvascular 
disease.  
 
When models included average 
A1C during follow-up or 
diabetes status at the end of 
follow-up, the association 
between regression to normal 
glucose regulation and lower 
prevalence of microvascular 
disease, no longer existed  
 
With regression to normal 
glucose regulation there was 
also a lower prevalence of 
nephropathy and retinopathy.  
 
As A1C increased so did MVD, 
nephropathy, and retinopathy  
Diabetes can be prevented or delayed in 
people with prediabetes 
 
Complications can also be prevented in 
prediabetics when early intervention is 
aimed at reducing body weight, lipids, 
blood pressure, and/or plasma glucose 
 
Regression to NGR is associated with 
lower prevalence of MVD, nephropathy, 
and retinopathy 
 
Limiting cumulative glycemic exposure is 
central in prediabetes care, whether they 
develop diabetes or not 
 
Highlights different relationships between 
the microvascular disease subtypes and 
glycemia over time 
 
Timing for glucose-lowering 
intervention(s) may well need to change 
as tools are developed to determine 




Snehalatha C., Mary S., 
Mukesh B., Bhaskar A.D., 
Vijay V. (2006). The 
Indian Diabetes 
Prevention Programme 
shows that lifestyle 
modification and 
metformin prevent type 2 
diabetes in Asian Indian 
subjects with impaired 
Progression to 
diabetes could be 
influenced by 
interventions in 
native Asian Indians 
with IGT who were 
younger, leaner, and 
more insulin resistant 
than multiethnic 
Americans, Finnish 
and Chinese  










Group 1 was the 
control (n = 136) 
 
Group 2 given 
advice on 
lifestyle 
modification (n = 
133) 
 
Group 3 was 
treated with 
Median follow-up period was 
30 months 
 
3-year cumulative incidences of 
diabetes were as follows; group 
1 (55.0percent), group 2 
(39.3percent), group 3 
(40.5percent), and group 4 
(39.5percent) 
 
Can prevent diabetes in native Asian 
Indian subjects with IGT using lifestyle 
modification  
 
Metformin also effective but in smaller 
doses (500 mg/day), which could be 
contributed to lower BMI of Asian 
Indians  
 
No additional benefit seen by combining 
lifestyle modification and metformin  
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glucose tolerance (IDPP-




metformin (n = 
133) 
 









was defined as 
development of 
T2DM 
Relative risk reduction for 
group 2 (28.5percent), group 3 
(26.4percent), and group 4 
(28.2percent) 
 
Number needed to treat to 
prevent one case of diabetes for 
group 2 (6.4), group 3 (6.9), 
and group 4 (6.5) 
 
Asian Indians have a very high 
progression rate of IGT to diabetes and 
therefore are considered high risk based 
off ethnicity  
 
LSM was more effective than metformin 
in all races, including the ethnic minority 
population, and the effect of metformin 
was lower in the thinner individuals 
 
Mechanisms responsible for the 
beneficial effects of interventions, 
independent of weight change, need to be 
analyzed 
 
It has also demonstrated the effectiveness 
that lifestyle modification involving 
moderate, but consistent, physical activity 
and diet modification help to prevent 
diabetes even in the Asian Indians, who 
have a high risk of developing diabetes 
Rhee, M., Herrick, K., 
Ziemer, D., Vaccarino, 
V., Weintraub, W., 
Narayan, K., Kolm, P., 
Twombly, J., & Phillips, 
L. (2010). Many 
Americans have pre-
diabetes and should be 
considered for metformin 





of Americans who 
would merit 
metformin treatment, 
according to ADA to 
prevent or delay 
development of 
diabetes 



































Isolated patients into three 
groups, IFG, IGT, and IFG and 
IGT. In SIGT, NHANES III, 
and NHANES, criteria for 
metformin consideration were 
met in 99, 96, 96percent with 
IFG and IGT, 31, 29, and 
28percent with IFT, and 53, 57, 
and 62percent with IGT.   
More than 96percent of individuals with 
both IFG and IGT are likely to meet 
criteria.  
 
Providers should perform oral glucose 
tolerance tests to find concomitant IGT in 
all patients with IFG.  
 
Roughly 1/12 adults meet criteria that 
may justify consideration of metformin 
treatment  















factor: age <60 
years, BMI ≥ 
35 kg/m 









Roberts, S., Barry, E., 
Craig, D., Airoldi, M., 
Bevan, G., & Greenhalgh, 
T. (2017). Preventing type 
2 diabetes: Systematic 
review of studies of cost-
effectiveness of lifestyle 
programmes and 
metformin, with and 
without screening, for 







and metformin, alone 


































Lifestyle programs and 
metformin appeared cost 
effective, but economic 
estimated varied. Intervention 
only programs more cost 
effective than programs that 
included screenings. Longer the 
period evaluated, more cost-
effective.  
 
Insufficient evidence to 
determine whether lifestyle 
programs are more cost 
effective then metformin or 
Preventing diabetes is complex and can 
be expensive. Although evidence is 
insufficient regarding what direction is 
most cost-effective, it is important to 
consider the advantages and 
disadvantages for your patient that is 
unique to them. Are you going to be 
spending more money in the beginning 
(lifestyle interventions and metformin 
cost) but ultimately saving cost by 
preventing patients delay to T2DM and 
complications associated with it.  









– used to assess 
study quality.  
whether low-intensity 
interventions are more cost 
effective then high intensity.  
Robertson, C. (2012). The 
role of the nurse 
practitioner in the 
diagnosis and early 
management of type 2 
diabetes. Journal of the 
American Academy of 
















N/A Multifactorial approach is 
required to deal with T2DM.  
-Lifestyle changes most 
important  
-Metformin and TZDs – 
effective with IGT and higher 
BMI 
 
Treatment that is multifactorial and 
personalized is most effective. Lifestyle 
changes such as increasing exercise or 
activity and reducing weight are most 
important, but metformin shown to be 
effective in patients with IGT and higher 
BMI. Pharmacological treatment and 
lifestyle interventions together with the 
control of cardiovascular risk factors are 
main strategies.  
Sheng, Z., Cao, J. Y., 
Pang, Y. C., Xu, H. C., 
Chen, J. W., Wang, R., 
Zhang, C. S., Wang, L. 
X., & Dong, J. (2019). 
Effects of lifestyle 
modification and anti-
diabetic medicine on 
prediabetes progress: A 








pre-diabetes is a risk 
factor for T2DM it is 
essential to identify 
effective preventive 
strategies, and to 
clarify direction of 


































Lifestyle modifications and 
anti-diabetic medications 
improved physical conditions, 
including weight loss, blood 
glucose and pressure 
 
Progression of diabetes can be 
delayed to varying degrees by 
lifestyle and pharmacological 
interventions, except for ACE 
Inhibitors, statins, 
sulfonylureas, and vitamin D 
 
 
There is firm evidence that lifestyle 
modifications and metformin reduce 
incidence of diabetes with an average 
reduction of 20percent 
 
Lifestyle modifications promising long-
term strategies involving nutrition, 
exercise, and weight loss contributed to 
the following: reduction of BMI, body 
weight, waist and hip circumference, 
systolic and diastolic pressure, fasting and 
2-h postprandial blood glucose, and total 
cholesterol  
 
Complications of diabetes increases 
patient suffering and mortality 
 













Effective interventions early on can 
reduce the personal and public health 
burden of diabetes  
 
More relevant trials needed to reinforce 
or complement review, focusing on 
clinical complications and cost-
effectiveness  
Souto, S., Souto, E., 
Braga, D., & Medina, J. 
(2011). Prevention and 
current onset delay 
approaches of type 2 
diabetes mellitus 
(T2DM). European 
















N/A Multifactorial approach is 
required to deal with T2DM.  
-Lifestyle changes most 
important  
-Metformin and TZDs – 
effective with IGT and higher 
BMI 
 
Treatment that is multifactorial and 
personalized is most effective. Lifestyle 
changes such as increasing exercise or 
activity and reducing weight are most 
important, but metformin shown to be 
effective in patients with IGT and higher 
BMI. Pharmacological treatment and 
lifestyle interventions together with the 
control of cardiovascular risk factors are 
main strategies.  
Tseng, E., Greer, R., 
O’Rourke, P., Yeh, H.-C., 
McGuire, M., Clark, J., & 
Maruthur, N. M. (2017). 
Survey of primary care 
providers’ knowledge of 
screening for, diagnosing 
and managing 







knowledge of risk 












and beliefs about 
prediabetes 























6percent PCPs correctly 
identified all risk factors that 
should prompt screening 
 
17percent PCPs correctly 
identified laboratory parameters 
for diagnosis 
 
90percent PCPs reported close 
follow-up 
 
11percent PCPs referred to a 
behavioral weight loss program  
 
PCPs need to address gaps in knowledge 
regarding prediabetes (risk factors and 
diagnostic parameters) and the 
underutilization of behavioral weight loss 
programs  
 
      70 
about 
prediabetes 
Patient-related factors are 
important barriers to lifestyle 
change and metformin use  
UK Prospective Diabetes 
Study Group. (1998). 
Effect of intensive blood-
glucose control with 
metformin on 
complications in 
overweight patients with 
type 2 diabetes (UKPDS 




Patients with T2DM, 
blood glucose control 
decreases progression 
of microvascular 





metformin has any 
specific advantage or 
disadvantage  























and 951 were 
assigned 
intensive control. 
Of the 951, 265 











86 died or no 
longer attended 
clinics. Of the 
1148 patients left 
(who had 
elevated FPG), 
211 not eligible 
due to FPG <6. 
A1C was 7.4percent in the 
metformin group compared to 
8.0percent in conventional 
group 
 
Patients taking metformin had 
risk reduction of 32percent for 
any diabetes-related endpoint, 
42percent for diabetes-related 
death, and 36percent for all-
cause mortality compared to 
conventional group 
 
Metformin showed greater 
effect than chlopropamide, 
glibenclamide, or insulin for 
any diabetes-related endpoint, 
all-cause mortality, and stroke  
 
Adding metformin to 
sulphonylurea-treated patients 
increased risk of diabetes-
related death 
 





Metformin appears to decrease the risk of 
diabetes related endpoints in overweight 
diabetic patients 
 
Associated with less weight gain and 
fewer hypoglycemic attacks than insulin 
and sulphonylureas, and should be 
considered first-line pharmacological 
therapy for diet-treated overweight 
patients 
 
Additional research and studies need to 
be conducted on the addition of 
metformin in patients already treated with 
sulphonylureas  
 
Findings may not apply to non-
overweight patients, but metformin seems 
to lower glycaemia in patients, regardless 
of obesity status (overweight or not)  
      71 
537 eligible for 
randomization 
and 411 not 
eligible due to 
FPG > 15. Of the 
537 eligible 269 
were on 
sulphonylurea 
along and 269 on 
sulphonylurea 
and metformin 
Wang, T., Eguale, T. & 
Tamblyn, R. (2013). 
Guidelines adherence in 
the treatment of patients 
with newly diagnosed 
type 2 diabetes: A 
historical cohort 
comparing the use of 
metformin in Quebec pre 
and post-Canadian 
Diabetes Association 
guidelines. BMC Health 




Measure the response 
of PCP who changed 
their initial therapy 
for patient with 
T2DM in relation to 
guideline changes 




















With new guidelines there was 
an increased use of metformin 




Physicians attitudes did not 
change regarding evidence-
based practice  
When new guidelines are initiated this 
change the practice of prescribing. If 
metformin is shown to be effective in 
preventing or delaying the progression to 
T2DM, the guidelines need to reflect this.  
 
 
 
 
 
 
